WallStSmart

Enterprise Products Partners LP (EPD)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 536% more annual revenue ($327.80B vs $51.56B). NVO leads profitability with a 37.2% profit margin vs 11.5%. EPD appears more attractively valued with a PEG of 2.18. NVO earns a higher WallStSmart Score of 74/100 (B).

EPD

Buy

52

out of 100

Grade: C-

Growth: 3.3Profit: 6.5Value: 7.3Quality: 5.0

NVO

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EPDUndervalued (+37.5%)

Margin of Safety

+37.5%

Fair Value

$56.69

Current Price

$37.19

$19.50 discount

UndervaluedFair: $56.69Overvalued

Intrinsic value data unavailable for NVO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EPD3 strengths · Avg: 8.3/10
Market CapQuality
$81.56B9/10

Large-cap with strong market position

P/E RatioValuation
14.0x8/10

Attractively priced relative to earnings

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

NVO6 strengths · Avg: 10.0/10
Market CapQuality
$202.85B10/10

Mega-cap, among the largest globally

P/E RatioValuation
10.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
71.4%10/10

Every $100 of equity generates 71 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
61.6%10/10

Strong operational efficiency at 61.6%

EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

Areas to Watch

EPD2 concerns · Avg: 3.0/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Revenue GrowthGrowth
-6.7%2/10

Revenue declined 6.7%

NVO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : EPD

The strongest argument for EPD centers on Market Cap, P/E Ratio, Price/Book.

Bull Case : NVO

The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.

Bear Case : EPD

The primary concerns for EPD are PEG Ratio, Revenue Growth.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

EPD profiles as a declining stock while NVO is a growth play — different risk/reward profiles.

EPD carries more volatility with a beta of 0.49 — expect wider price swings.

NVO is growing revenue faster at 24.0% — sustainability is the question.

NVO generates stronger free cash flow (12.0B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (74/100 vs 52/100), backed by strong 37.2% margins and 24.0% revenue growth. EPD offers better value entry with a 37.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enterprise Products Partners LP

ENERGY · OIL & GAS MIDSTREAM · USA

Enterprise Products Partners LP provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGL), crude oil, petrochemicals, and refined products. The company is headquartered in Houston, Texas.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?